OncoMatch/Clinical Trials/NCT06679101
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Is NCT06679101 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Belantamab mafodotin and Lenalidomide for multiple myeloma.
Treatment: Belantamab mafodotin · Lenalidomide · Dexamethasone · Daratumumab — The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
Lab requirements
Blood counts
Adequate organ system function as defined by the laboratory assessments
Kidney function
Adequate organ system function as defined by the laboratory assessments
Liver function
Adequate organ system function as defined by the laboratory assessments
Adequate organ system function as defined by the laboratory assessments
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · Mobile, Alabama
- GSK Investigational Site · Phoenix, Arizona
- GSK Investigational Site · Beverly Hills, California
- GSK Investigational Site · Pasadena, California
- GSK Investigational Site · Aurora, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify